Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.53 |
| ▸ | KDM1A | O60341 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PPIA | P62937 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30719648 | 1.00 | MRGPRX4 (0.53) | MRGPRX4KDM1AL3MBTL1MAPTMAPK1 | |
| SCHEMBL23258545 | 0.86 | PPIA (0.49) | MRGPRX4KDM1AL3MBTL1MAPTMAPK1 | |
| SCHEMBL23263852 | 0.86 | BRD4 (0.50) | MRGPRX4KDM1AL3MBTL1MAPTMAPK1 | |
| SCHEMBL4267531 | 0.84 | MRGPRX4 (0.63) | MRGPRX4KDM1AL3MBTL1MAPTMAPK1 | |
| SCHEMBL5571351 | 0.84 | MAOB (0.53) | MRGPRX4KDM1AL3MBTL1MAPTMAPK1 | |
| SCHEMBL8612029 | 0.84 | ERN1 (0.52) | MRGPRX4L3MBTL1S1PR5LMNA | |
| SCHEMBL1128800 | 0.84 | S1PR5 (0.52) | MRGPRX4KDM1AS1PR5LMNANPC1 | |
| SCHEMBL16231698 | 0.83 | FFAR1 (0.46) | MRGPRX4KDM1AL3MBTL1MAPTMAPK1 | |
| SCHEMBL8613876 | 0.82 | ERN1 (0.51) | MRGPRX4L3MBTL1LMNA | |
| SCHEMBL5244730 | 0.82 | L3MBTL1 (0.49) | MRGPRX4KDM1AL3MBTL1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104923079-A | Preparation method and application of hyamine cationic polyelectrolyte-anionic surfactant compound | UNIV ZHEJIANG | 2015-09-23 | — | — | CN | claimed |
| US-20250257074-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12173013-B2 | Synthetic processes and synthetic intermediates | TAXIS PHARMACEUTICALS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-110891566-B | Synthesis method and synthesis intermediate | 塔克西斯医药股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230339969-A1 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-10-26 | — | — | US | disclosed |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20210139508-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210139508-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| WO-2008080015-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | MRGPRX4 4036/4885KDM1A 2421/4885L3MBTL1 2040/4885 |
| US-20210139508-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TXN, TBXAS1, TXK | MRGPRX4 1760/4885KDM1A 4278/4885L3MBTL1 2848/4885 |
| US-20230339969-A1 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | HCRTR2, HCRTR1, CNR2 | MRGPRX4 112/4885KDM1A 855/4885L3MBTL1 3014/4885 |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MRGPRX4 2895/4885KDM1A 2465/4885L3MBTL1 794/4885 |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TXN, TBXAS1, TXK | MRGPRX4 1760/4885KDM1A 4278/4885L3MBTL1 2848/4885 |
| US-20250257074-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TXN, TBXAS1, TXK | MRGPRX4 1760/4885KDM1A 4278/4885L3MBTL1 2848/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MRGPRX4 2895/4885KDM1A 2465/4885L3MBTL1 794/4885 |
| US-12173013-B2 | Synthetic processes and synthetic intermediates | TXN, TBXAS1, TXK | MRGPRX4 1760/4885KDM1A 4278/4885L3MBTL1 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.